| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/09/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/20/2023 |
8-K
| Quarterly results |
| 01/18/2023 |
8-K
| Quarterly results |
| 11/21/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Investor presentation, Quarterly results |
| 10/24/2022 |
4
| Maccecchini Maria-Luisa (Director) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Granted 3,200 options to buy
@ $4.79, valued at
$15.3k
|
|
| 09/07/2022 |
4
| Fletcher Aaron G.L. (10% Owner) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Sold 5,170 shares
@ $5.2, valued at
$26.9k
Sold 1,275 shares
@ $5.2, valued at
$6.6k
Exercised (in-or-at-the-money) 26,100 options
@ $1.03, valued at
$26.9k
Exercised (in-or-at-the-money) 6,438 options
@ $1.03, valued at
$6.6k
|
|
| 09/07/2022 |
4
| Kreis Leslie W. (10% Owner) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Sold 5,170 shares
@ $5.2, valued at
$26.9k
Sold 1,275 shares
@ $5.2, valued at
$6.6k
Exercised (in-or-at-the-money) 26,100 options
@ $1.03, valued at
$26.9k
Exercised (in-or-at-the-money) 6,438 options
@ $1.03, valued at
$6.6k
|
|
| 08/09/2022 |
4
| SHARMA PANNA (President and CEO) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Granted 100,000 options to buy
@ $5.6, valued at
$560k
|
|
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
3
| Maccecchini Maria-Luisa (Director) has filed a Form 3 on Lantern Pharma Inc. |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/03/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/25/2022 |
8-K
| Other Events Interactive Data |
| 03/22/2022 |
SC 13D/A
| Bios Equity Partners, LP reports a 18.1% stake in Lantern Pharma Inc. |
| 03/22/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/21/2022 |
4
| Kreis Leslie W. (10% Owner) has filed a Form 4 on Lantern Pharma Inc.|
Txns:
| Exercised (in-or-at-the-money) 60,432 shares
@ $189152.16, valued at
$11430.8M
Exercised (in-or-at-the-money) 35,347 shares
@ $110636.11, valued at
$3910.7M
Exercised (in-or-at-the-money) 60,432 options to buy
@ $0
Exercised (in-or-at-the-money) 35,347 options to buy
@ $0 |
|
| 03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/10/2022 |
8-K
| Investor presentation |
| 01/24/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/11/2022 |
SC 13G/A
| Empery Asset Management, LP reports a 0% stake in Lantern Pharma Inc. |
|